Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide)

Share:

Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an …
MarketWatch
JERUSALEM, September 3, 2013 /PRNewswire via COMTEX/ — Oramed Pharmaceuticals Inc. (nasdaqcm:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has submitted a pre-Investigational New Drug … capsule …

http://www.marketwatch.com/story/oramed-submits-pre-ind-package-to-fda-for-ormd-0901-oral-exenatide-an-oral-glp-1-analog-for-the-treatment-of-type-2-diabetes-2013-09-03?reflink=MW_news_stmp

Tweet